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Simple Summary: Drug repurposing is an accelerated route for drug development and a promising
approach for finding medications for orphan and common diseases. Here, we compiled databases
that comprise both computationally- or experimentally-derived data, and categorized them based
on quiddity and origin of data, further focusing on those that present high throughput omic data or
drug screens. These databases were then contextualized with genome-wide screening methods such
as CRISPR/Cas9 and RNA interference, as well as state of art systems biology approaches that enable
systematic characterizations of multi-omic data to find new indications for approved drugs or those
that reached the latest phases of clinical trials.
Abstract: Modern drug discovery through de novo drug discovery entails high financial costs,
low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for
overcoming these issues by re-evaluating biological targets and modes of action of approved drugs.
Coupling high-throughput technologies with genome-wide essentiality screens, network analysis,
genome-scale metabolic modeling, and machine learning techniques enables the proposal of new
drug–target signatures and uncovers unanticipated modes of action for available drugs. Here,
we discuss the current issues associated with drug repositioning in light of curated high-throughput
multi-omic databases, genome-wide screening technologies, and their application in systems
biology/medicine approaches.
Keywords: drug repositioning; genomic screens; machine learning; systems pharmacology;
systems medicine
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1. Introduction
One of the first intentional and remarkable efforts for drug repositioning was carried out in
1987, when human immunodeficiency virus (HIV) became a full-blown pandemic with no known
treatments. Prior to that time, azidothymidine (AZT) had been under development as an anticancer
drug and had failed during clinical trials due to the absence of efficacy. Surprisingly, it took just
over two years to move from the initial demonstration of AZT’s anti-HIV property to its FDA
approval [1]. Empirical investigations of repositionable drugs have led to the rescue of the utility
of many FDA-approved chemicals [2,3]. Empirical drug repositioning represents the process of
finding an unknown target for a known drug in vitro. It has been proposed that empirical drug
repositioning could be a starting point for the process of drug repurposing by the in vitro screening of
known drugs or drug-like molecules, in order to identify and validate candidates for repositioning
which result in the following advantages: The knowledge on a potential new disease setting will be
increased; a serendipitous, or hypothesis-free, assessment of compounds will be achieved by testing
multiple compounds with different modes of action; and data-driven choices will be produced for
further investigations in more complex phenotypic or in vivo tests. As an example, an FDA-approved
drug library of 640 compounds was screened and 10 of them, including tamoxifen and raloxifene,
were proposed as compounds that are able to protect hair cell loss in response to known inner ear
mechanosensory hair cell toxins, such as neomycin, gentamicin, kanamycin, and cisplatin, which cause
hearing impairment and balance disorders [2]. In rational drug repurposing, the target is known
from the beginning and subsequently, the goal is to find a previously FDA-approved compound
which can interact with the target of interest [4]. In empirical drug repositioning, a large number of
combinatorial compounds are prepared and tested. Rational drug repurposing reduces the number
of candidates in the early stages of an investigation and identifies entities with a high probability
of success [5]. Drug repurposing, also known as drug rescuing, repositioning, redirecting, tasking,
recycling, or reprofiling, is a suitable approach for reusing existing drugs.
There are several reasons for the global need to repurpose currently approved drugs, instead of
developing them de novo, including low success rates. At the beginning of 2020, there were 261,163
ongoing clinical trial studies (February 2020, www.clinicaltrials.gov) distributed all over the world
(Figure 1a). In 2019, there were 318,901 ongoing clinical trials; while it is unclear how many of these
clinical trials featured de novo drug design, only 48 novel drugs were approved for usage by the FDA
(www.fda.gov). Taking this >95% failure rate into account, drug development is an extremely time- and
resource-consuming process [3] insofar as the rate of success is almost 1 out of 10,000 (Figure 1b) [4].
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Figure 1. (a) Drug repositioning significantly cuts drug development costs and lengths of time.
The distribution of the total number of conventional drug development studies and approved drugs
for marketing is shown in the table and map. The USA, north North America, and Europe have the
highest number of ongoing clinical trials [5]. (b) Two different methods for drug development are
compared. The number of components (biological and/or chemical drug candidates), as input into de
novo drug development, is 2000 times higher than drug repositioning, while drug repositioning may
start in more advanced clinical trial phases and save several years when trying to find new treatments
for emerging diseases.
On the other hand, whilst swift development for emerging diseases such as Covid-19 caused by
SARS-Cov-2 is crucial, conventional procedures for drug development last more than 10 years [6,7].
FDA-approved drugs, or even those which have passed at least a phase I clinical trial (i.e., with proven
human safety), could be considered as alternatives for rapid drug development. Considering that
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these drugs have passed at least a phase I clinical trial for one particular affliction, they could directly
enter phase II or III of clinical trials for a second and unrelated indication. This path would take about
two years, which is considerably shorter than the >14 years required for de novo drug development
(Figure 1b), with an associated substantial cost reduction [3,8].
A single gene may be involved in two or more biological pathways or diseases and by targeting this
gene, two unrelated diseases may be remedied. In addition, several mutations may disrupt the same
biological pathway. In this case, all drugs which have similar effects on this pathway could be a candidate
for repurposing studies [9]. For instance, trametinib is a mitogen-activated protein kinase kinase
(MEK) pathway inhibitor, and is used for the treatment of leukemia and pancreatic cancer [9]. On the
other hand, drug off-targeting could be another procedure employed for drug repositioning when
the biological activity of a drug is different from its intended biological target. Despite being known
as a common contributor to drug side effects, in some cases, off-target activity can be advantageous
for therapeutic purposes. For example, the repurposing of the antimineralocorticoid and diuretic
spironolactone, which is known to produce feminization and gynecomastia due to antiandrogen
activity as side effects, could be used as an antiandrogen in the treatment of conditions like acne and
hirsutism [10]. Additionally, sildenafil (Viagra®, Revatio®) [11] and minoxidil (Rogaine®) were
originally developed for hypertension [12], but their off-target effects during trials were further explored
in erectile dysfunction and promoted hair growth, respectively. Recent studies have aimed to make use
of high-throughput datasets and computational approaches for the prediction of off-targets, in order to
propose suitable repurposable drugs [13,14]. For instance, Rao et al. [13] developed the computational
Off-Target Safety Assessment (OTSA) using more than 1 million compounds to identify potential
off-target interactions that could be linked to predictable safety issues. In addition, Huang et al. [14]
combined in vitro and in silico approaches to develop an integrative framework for the systematic
identification of on-/off-target pathways and clarification of the underlying regulatory mechanisms.
Drug repositioning can be done based on prior knowledge or serendipity. This can be aided with
the application of high-throughput screening, including CRISPR-Cas9 screening, RNAi Screening,
and the application of systems medicine approaches for purposeful drug repositioning. One of the
goals of genome-wide screening experiments is to generate and screen a population of genes to
identify a particular phenotype or pathway and accordingly propose drug targets. The outcomes
from screening studies could prepare the stage for systems medicine to integrate multi-omic data for
accurate predictions of a drug’s mode of action, targets, and disease associations.
2. High-Throughput Resources for the Identification of Drug Targets and Repositioning of Drugs
Precision medicine aims to develop efficient therapeutic strategies with fewer side effects matching
the unique disease signatures in specific cohorts, thus making use of precision pharmacology [15].
However, the accurate identification of suitable targets and repurposable drugs relies on databases
(DBs) of chemical and biological compounds and high-throughput omic datasets. Here, we classified
DBs indicated as suitable resources for the identification of drug targets and revealing the
chemical–phenotype association according to the quiddity and origin of data, as well as whether they
rely on computational- or wet lab-based approaches.
One may distinguish five groups of DBs [16] and their content (Figure 2) as follows: (i) Raw
DBs, whose data are indirectly involved in drug repositioning and include literature curation,
manual data uploading, data curation, integration, and clinical data; (ii) Target-based DBs containing
drug targets and related information, including information on pathways, enzymes, side effects,
genes, and protein targets; (iii) Specific DBs, which are those associated with specific software,
disease data, and geographical information; (iv) Drug Design DBs, which typically include small
molecules, 3D molecular structures, and molecular replacement information; and (v) Tool-based DBs,
which embrace drug repositioning-related tools and include net-based tools (data mining through
network theory) and simple tools (other approaches for data mining). These DBs rely on many different
types of biological and chemical data and present different content availabilities and assays (Table S1).
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Several DBs present particularly useful resources for data-driven analyses given their biological content,
which often comprises high-throughput datasets (Table 1).
Figure 2. Key databases as primary resources for drug repositioning. Databases (DBs) can be
divided into five classes, including Drug Design DB, Specific DB, Target-based DB, Tool-based
DB, and Raw DB. The content of each DB is shown with an edge to the subcategories. Refer to
Table S1 for a full description. DBs with omics and high-throughput datasets are colored in yellow.
Subcategories: 3D: three-dimensional information; CLI: clinical; CUA: curation; DI: disease; ENZ:
enzyme; GE: gene target; GO: geographic; INT: integration; Lit: literature; MAU: manual; MO:
molecular information; MT: multidrug; NB: net-base; PR: protein target; PTH: pathway; SDE:
side effect; ST: simple tool; TR: software. Databases: ACHI: Achilles; ARREXP: ArrayExpress;
BLGe: BaderLabGenes; BIOM: Biomodels; BMRB: Biological Magnetic Resonance Data Bank; CCOM:
Cancer Common; CCLF: cancer cell line factory; CCLE: Cancer Cell Line Encyclopedia; CFBs: Clearity
Foundation Biomarkers; CFCT: Clearity Foundation Clinical Trial; CGI: Cancer Genome Interpreter;
ChBLI: The ChEMBL Bioactivity Database; CIViC: Clinical Interpretations of Variants in Cancer; CKB:
The Jackson Laboratory Clinical Knowledgebase; CTDB: Cheminformatic Tools and Databases; CMI:
Caris Molecular Intelligence; CORUM: comprehensive resource of mammalian protein complexes;
CTR: Cancer Therapeutics Response Portal; CTD: The Comparative Toxicogenomics Database; CTRP:
Clinical Trials Reporting Program; dGene: The Druggable Gene List; DGIdb: drug–gene interaction
database; DMAP: Dependency Map; DMC: Drug Map Central; DNET: Drug-Disease Network database;
DoCM: Database of Curated Mutations; DPTH: Drug Pathway database; DRUGB: DrugBank; DRHUB:
drug repurposing hub; DRAR: Drug Repurposing Adverse Reaction; DSDB: Drug Signatures Database;
DSIG: DrugSig; DTW: Drug Target Web; ENCODE: Encyclopedia of DNA Elements, Entrez, Ensembl;
FDA: FDA Pharmacogenomic Biomarkers; FOGe: Foundation One Gene; GEO: Gene Expression
Omnibus; GPIs: Guide To Pharmacology Interactions; GPCR: G-protein-coupled receptors assay bank;
GDSC: Genomics of Drug Sensitivity in Cancer; GO: The Gene Ontology; GRNAi: GenomeRNAi;
GSEA(MSigDB): Gene Set Enrichment Analysis; GSDB: Gene Set Database; GTPGe: Guide To
Pharmacology Genes; HCa: Hingorani Casas; HIVRT: HIV Drug Resistance Database; HkG: Hopkins
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Groom; HTRCP: host transcriptional response connectivity map; L1000: Library of Integrated
Network-based Cellular Signatures (LINCS) L1000; MCGCT: My Cancer Genome Clinical Trial;
METN: Metlin; META: Metabolic Atlas; MskIm: Memorial Sloan Kettering IMPACT; NCI:
Cancer Gene Index; NCATS: National Center for Advancing Translational Sciences; NNFIN:
network-based similarity finder; ODB: Ontario database; OGEE: Online GEne Essentiality; OMDI:
Omics Discovery Index (omicsdi); OncoKB: A Precision Oncology Knowledge Base; PACO: pathway
commons; HPA: Protein Atlas; PBL: ProBiS-ligands; PDTD: Potential Drug-Target Database; PhGKB:
The Pharmacogenomics Knowledgebase; PRIDE: PRoteomicsIDEntifications (PRIDE) database; PROM:
Promiscuous; RepDB: Repurpose DB; RLa: RussLampel; SAINT: Significance Analysis of INTeractome;
SBIOS: Swiss BIOisostere; SCYP: Super Cytochrome P450; SIDER: Side Effect Resource; SMPDB:
Small Molecule Pathway Database; TALC: Targeted Agents in Lung Cancer; TCSBN: tissue- and
cancer-specific biological networks; TDR: Tropical Diseases Research; TDGCT: The Druggable Genome
(TDG) Clinical Trial; TEND: trends in the exploitation of novel drug targets; TTD: Therapeutic
Target Database.
Table 1. DBs and their associated omic data as useful resources for drug repositioning.
Database Type of Omics data Link Ref.
ARREXP Functional genomics data https://www.ebi.ac.uk/arrayexpress/ [17]
BMRB Proteomics, metabolomics http://www.bmrb.wisc.edu/ [18]
CCLE Genomic data https://portals.broadinstitute.org/ccle [19]
DRUGB Transcriptomics https://www.drugbank.ca/ [20]
DMAP Transcriptomics,proteomics https://depmap.org/portal/ [21]
ENA Genomics, transcriptomics https://www.ebi.ac.uk/ena [22]
ENCODE Genomics, transcriptomics https://www.encodeproject.org/ [23]
ENTREZ Genomics, transcriptomics,proteomics, taxonomics
https://www.ncbi.nlm.nih.gov/Class/
MLACourse/Original8Hour/Entrez/ [24]
ENSEMBL Genomics, transcriptomics https://www.ensembl.org/index.html [25]






HIVRT Genomics, phenomics https://hivdb.stanford.edu/ [28]












HPA Proteomics https://www.proteinatlas.org/ [33]
PRIDE Proteomics https://www.ebi.ac.uk/pride/archive/ [34]
NCATS Chemical genomics https://ncats.nih.gov/ [35]
OGEE Genomics, transcriptomics http://ogee.medgenius.info/browse/ [36]
REMC Epigenomics http://www.roadmapepigenomics.org/ [37]
TDR Genomics https://tdrtargets.org/ [38]
3. Computational- and Wet Lab-Based Assay DBs
Among the assay-based DBs, one may consider two general groups of databases based on
the main approaches they use to obtain data, including computational- and wet lab-based assays.
Computational-based databases are those which only benefit from in silico approaches, whether
using primary assays such as data curation or advanced approaches, including network analysis.
Wet lab-based datasets acquire data through wet lab assays.
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3.1. Computational-Based Assay DBs
Various computational methods may be employed to acquire or collect biological data. For instance,
text mining is a powerful technology for swiftly sifting key information through the vast quantities of
biomedical literature. Text-mining techniques discover and extract new and unknown information
from different resources, including databases, websites, books, reviews, and articles [39]. Manual data
curation filters research results as they are generated, which means it unifies data for long-term
sustainability and usage. In addition, this method monitors the reliability, reusability, and accessibility
of obtained data [40]. Through integration, data from different sources may be processed and combined
into a single, unified view [41,42].
Many datasets have followed one or a combination of these procedures, with or without
experimental results, to design a comprehensive biological DB. For instance, GenomeRNAi (GRNAi) [43]
is a manual extraction of phenotypes from RNAi screening in Drosophila and Homo sapiens literature,
in addition to information about resources of RNAi reagents and their predicted quality. A dependency
map (DMAP) [19] uses predictive modeling to collect and curate data from subdivisions of the
DepMAP project, in order to propose gene–drug–disease associations. Gene Set Enrichment Analysis
(GSEA)-MSigDB benefits from the gene set enrichment analysis method [42] and the Guide To
Pharmacology Interactions (GPIs) [44], and Gene Set Database (GSDB) [45] benefit from data integration
to present results.
In the case of methods used to retrieve drug–target associations, the Drug-Disease Network
database (DNET) [46] uses differential co-expression analysis to obtain 1326 disease relationships
among 108 diseases. Tissue- and cancer-specific biological networks (TCSBN) apply co-expression
and integrated network analysis for 17 cancers and three tissues [33,47]. Additionally,
Promiscuous (PROM) [48] organizes and curates data based on network concepts to predict new usages
for existing drugs, considering the side effects. The Comparative Toxicogenomics Database (CTD) [49]
provides manually curated information about chemical–gene/protein–disease associations, and the drug
repurposing hub (DRHUB) [50] drug–gene interaction database (DGIdb) [51], DrugBank (DRUGB) [20],
Small Molecule Pathway Database (SMPDB) [52], and Repurpose DB (RepDB) are comprehensive
resources for gene targets, drugs and their categories, gene–drug interactions (DGIdb), and small
molecule pathways (SMPDB). RepDB [53] is a compendium of drug targets, repurposed drugs,
and their associated primary and secondary diseases. This database combines information on
253 drugs and 1125 diseases and using enrichment analysis, it determines key biological pathways,
functional mechanisms, physicochemical features, and side effects associated with successfully
repositioned drugs. These resources can help other researchers to design a better investigation
for finding new targets for approved or even repositioned drugs.
Several repositories allow for manual and ununified dataset depositing, and include
ArrayExpress [17] and Gene Expression Omnibus (GEO) [27], which contain functional genomics
data from high-throughput functional genomics experiments. The Biological Magnetic Resonance
Data Bank (BMRB) [18] contains experimental and derived data gathered from nuclear magnetic
resonance (NMR) spectroscopic studies of biological molecules. BioModels [54] is a repository of
mathematical models of biological and biomedical systems. In order to systematically analyze
these repositories, some computational tools have aimed to integrate information for purposes that
include proposing therapeutic targets. For instance, the Omics Discovery Index (OMDI) [32], as an
open-source platform that enables access to and discovery and dissemination of omics data sets,
may be used to integrate proteomics, genomics, metabolomics, and transcriptomics data sets from
dozens of databases and repositories which have agreed on a common metadata structure framework
and exchange format, and have contributed to OMDI. Similarly, the Metabolic Atlas [31] integrates
open source genome-scale metabolic models. In addition, CTD utilizes various tools to discover the
drug–target association through data provided by many datasets and repositories, including The
Pharmacogenomics Knowledgebase (PhGKB) [55], DRUGB [20], geographic (GO) [56], and NCBI [57].
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3.2. Wet Lab-Based Assay DBs
DBs containing information which is created through experimental approaches can provide
the information required for many other projects and computational assay-based DBs. In this case,
three different purposes might be considered. In the first group, projects may encompass large
amounts of ununified raw data (i.e., Big Data), but this does not enable their direct application in
drug repositioning. The second group includes projects which benefit from a specific approach and
directly create relevant information about drugs, gene targets, protein targets, or any other data which
clearly pave the way for drug repositioning. Finally, the third group is comprised of projects that aim
to develop experimental methods in order to escalate the efficiency of experimental approaches.
The value of data provided by the first group is undeniable and large amounts of time and many
efforts have been devoted to developing them. However, whilst most of the provided data are not
directly aimed at drug repositioning, they may nevertheless be mined by advanced computational
approaches. Many consortiums have achieved strikingly crucial advances in coordinating these
efforts. For instance, the goal of the ENCODE consortium [23] is to build a comprehensive list of
functional elements in the human genome, including elements that act at the protein and RNA levels,
and regulatory elements that control cells and circumstances in which a gene is active. Systematically
mapped regions of transcription, transcription factor associations, the chromatin structure, and histone
modification in ENCODE have enabled researchers to assign biochemical functions for 80% of previously
unknown protein-coding genomic regions. REMC [37], which is a similar project to ENCODE, aimed to
identify DNA methylation, histone modifications, chromatin accessibility, and small RNA transcripts in
primary human tissues. Another interesting example in this group is the LINCS L1000 [58,59] project,
which developed its own method to quantify transcriptomic data from treated and untreated cancer
cell lines. L1000 is a cost-effective high-throughput method that can be used to estimate genome-wide
mRNA expression on a large scale based on the direct measurement of a reduced representation of the
transcriptome (978 landmark genes), which captures most of the information contained in the entire
transcriptome [58] and computationally infers the remaining transcriptome [27].
Other DBs enable user queries to identify drug targets and repositionable drugs. For instance,
the Achilles (ACHI) project, which is one of the subdivisions of DMAP and provides its essential data,
systematically identifies and catalogs gene essentiality in genomically characterized cancer cell lines
through genome-scale RNAi and CRISPR-Cas9 genetic perturbation reagents, in order to identify those
genes that affect cell survival [21]. We discuss RNAi and CRISPR-Cas9 screens below. Identifying and
targeting cancer dependencies with small molecules is the aim of the Cancer Therapeutics Response
Portal (CTR) [60], which has accelerated the discovery of patient-matched cancer therapeutics. CTR has
generated a set of 481 small-molecule probes and drugs that selectively target distinct nodes in cell
circuitry and that collectively modulate a broad array of cell processes. In addition, the sensitivity of
860 deeply characterized cancer-cell lines toward Informer set compounds is quantitatively measured
and connected to cancer features, including mutations, gene expression, copy-number variation,
and lineages, and relevant results are freely available on the CTR database [61]. The Cancer Cell Line
Encyclopedia (CCLE) provides public access to genomic data, analysis, and visualization for cancer cell
lines [19]. It is one of the many large panels of comprehensively characterized human cancer models
and helps to study genetic variants, candidate targets, and small-molecule and biological therapeutics.
In addition, it may be used to identify new marker-driven cancer dependencies by examining genetic,
RNA splicing, DNA methylation, histone H3 modification, microRNA expression, and reverse-phase
protein array data for 1457 cell lines [19]. The Genomics of Drug Sensitivity in Cancer (GDSC)
DB characterized many human cancer cell lines and screened them with hundreds of compounds,
and accordingly, made drug response data and genomic markers of sensitivity available [26].
Among the projects that aim to escalate the experimental efficiency is the National Center
for Advancing Translational Sciences (NCATS) consortium at NIH. The aim of this consortium
is to develop, demonstrate, and disseminate tools and solutions to be used by all translational
investigators. NCATS arms researchers with translational science information by making new methods,
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data, and information publicly available. For instance, the Assay Guidance Manual (AGM), as a
procedure for data transparency and release in NCATS, resulted in the successful development of
robust, early-stage drug discovery assays [62]. In addition, in the case of the availability of data,
NCATS serves the pharmacological industry through PubChem [63] (small organic molecules and their
activities against biological assays), the NCATS pharmaceutical collection [64] of active pharmaceutical
ingredients and small molecules, and small molecule probes [65].
Another example of efforts aiming to escalate the experimental efficiency is the design and
implementation of high-throughput G-protein-coupled receptor (GPCR) assays in GPCR Assay Bank
that allow the cost-effective screening of large compound libraries, in order to identify novel drug
candidates [66]. GPCRs are some of the most successful therapeutic target assays for a broad
spectrum of diseases and mediate many important physiological functions. The GPCR Assay
Bank is the largest readily accessible collection of approved drugs and has several subdivisions
(https://web.duke.edu/gpcr-assay/my_screening.html), including Johns Hopkins Clinical Compound
Library (JHCCL) (1514 compounds), KinaseGold Library (3893 compounds), PresTwick Library
(1120 compounds), Sigma Kinase Library (97 compounds), Steroid Drug Library (1659 compounds),
Tripos Library (50K compounds), TimTec NPL (Natural Product Library, 720 compounds), ActiProbe-5K
(5K compounds), and Chemdiv Library (https://www.chemdiv.com/) (299,408 compounds).
4. Application of Genome-Wide Screening in Drug Repositioning
Functional genetic screening connects genes or genetic elements to phenotypes-of-interest.
In this case, several methods have been gradually developed [67]. RNA interference (RNAi)
oligonucleotides for loss-of-function studies [68] and cDNA overexpression libraries for gain-of-function
studies [69] were performed prior to the clustered regularly interspaced short palindromic repeats
(CRISPR)-associated Cas9 endonuclease system [67] and systems biology approaches [70]. All of these
methods, especially CRISPR-Cas9, revealed a wealth of mechanistic insights, from drug resistance in
cancer to neuronal toxicity in amyotrophic lateral sclerosis, and also made prerequisite information for
drug repositioning by introducing drug targets available.
4.1. Drug Target Identification through RNA Interference Screening
RNA interference (RNAi) is a post-transcriptional gene regulating system which benefits from
small noncoding RNAs and is utilized for the sequence-specific knockdown of a gene’s function [4,71].
Small interfering RNAs (siRNAs), individually or as a pool of synthetic RNAs, are designed to
specifically target unique messenger RNAs (mRNA) for a period of time or permanently [72].
High-throughput RNAi screening leads to the discovery of gene functions and its applications
have been proven in many fields, such as infection, cancer, obesity, and aging.
RNAi can be introduced to the cell in various ways (Figure 3a), but all of them will end up with the
siRNA duplex(es) entering the RNA-induced Silencing Complex (RISC) pathway. RISC can unwind
and cleave the RNAi and realize the guide strand to pair with the target mRNA via perfect sequence
complementarity. Afterwards, the RISC which is activated and specified by guide strand cleaves the
target mRNA and accordingly, the protein production is abolished [73].
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Figure 3. Various RNA interference (RNAi) constructs used for temporary or permanent gene silencing
and a general workflow of small interfering RNA (siRNA) screening towards drug repositioning
(adapted from [72]). (a) siRNA, endoribonuclease-prepared siRNA (esiRNA), and long double-strand
RNA (dsRNA), as naked RNAs, can be introduced to the cell through many pathways, such as lipid-based
transfection reagents or electroporation, or active uptake by target cells through receptor-mediated
endocytosis. Inside the cytoplasm, dsRNA is cleaved by endonucleases. Then, the obtained siRNA,
along with the directly introduced siRNAs and siRNAs coming from the nucleus of hard-to-transfect
cells which were achieved from viral vectors carrying siRNA or short hairpin RNA (shRNA) expression
cassettes, are loaded into the RNA-induced Silencing Complex (RISC) to facilitate gene expression
knock down. (b) Drug targets and available compounds are determined by in silico pathway analyses
and database mining after two-step in vitro screening. Prior to clinical analysis, the efficiency of these
drug candidates can be validated by in vitro and in vivo approaches.
In Figure 3b, we provide a general workflow of siRNA screening towards drug repositioning.
After transfection of the cell culture system with an siRNA library, a particular disease model (e.g.,
specific cancer) is induced in the cultured cells. Pre-determined endpoint assays are conducted at
desired time points to yield hits (the genes which have an influence on disease) and lists of gene hits are
compiled. Subsequently, these genes are validated in various conditions, such as different cell types,
viruses, inductions, and different end-point assays. After the detection of a target gene, validation can
be conducted by single siRNAs instead of siRNA pools. Eventually, these genes can be potentially
targeted as a therapeutic disease intervention strategy [72].
Among the successful experiments involving genome-wide RNAi screening is the application of a
library of 74,905 retroviral shRNAs targeting 32,293 unique human transcripts to determine synthetic
lethal interactions with the Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene, which is
the isoform most commonly mutated in human cancers [74]. More recently, Takai et al. carried out
a genome-wide RNAi through the GeneNet h50K shRNA library, which is composed of ~200,000
lentiviral shRNAs and more than 47,000 transcript targets, in order to identify genes with a synthetic
lethal interaction with epithelial cellular adhesion molecule (EpCAM) as a potential therapeutic target
for the EpCAM + AFP + Hepatocellular carcinoma subtype [75].
RNAi high-throughput screening, in spite of allowing for the swift discovery of the molecular
basis of many diseases, and the identification of potential pathways for developing safe and effective
treatments [72], presents issues associated with off-targeting [71].
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4.2. Drug Target Identification through Genome-Wide CRISPR-Cas9 Screening
CRISPR-Cas9 genome-wide essentiality screens present suitable technologies for improving target
prediction while minimizing off-targeting, thus improving on RNAi screens. Repurposing CRISPR as an
RNA-guided platform for the sequence-specific control of gene expression was developed in 2013 [76].
Since then, many efforts have been made to conduct gene screening through this approach [9,77,78].
CRISPR-Cas9-based technology allows the discovery of efficient and precise new or repurposed
drug candidates for genomic or proteomic targets. Systematic screenings of genes associated with a
disorder can be conducted by combining the Cas9 endonuclease and a pooled guide RNA (gRNAs)
library [75,79,80]. The gRNAs direct the Cas9 enzyme for DNA double strand cleavage, while different
kinds of mutations might be introduced by the error-prone Non-Homologous End Joining (NHEJ)
DNA repair mechanism [81,82]. Therefore, it is possible to perturb many target genes simultaneously
by using predesigned pooled gRNAs.
CRISPR-based gene activation (CRISPRa) and inhibition (CRISPRi), representing more powerful
tools than RNA interference (RNAi) libraries, are highly useful in screening for gain and loss of function
studies, respectively. Positive and negative selection using CRISPR libraries can clarify drug resistance
mechanisms and survival-essential genes as drug targets [83]. CRISPR-Cas9 screening is currently
employed to systematically investigate genes associated with lethal phenotypes and subsequently,
propose drug targets at the gene and/or protein levels and accordingly identify likely repositionable
drug candidates [84–87] (Figure 4).
Fused genes are two independent genes formed through structural rearrangements,
the transcription of adjacent genes, or the splicing stage of pre-messenger RNA, which may lead to the
dysfunctionality of modified genes and deregulation of associated genes, and afterward, the probable
overexpression of oncogenes and/or decreased expression of tumor suppressor genes [88].
One of the first large-scale systematic analyses of thousands of gene fusions in human cancers
analyzed 1034 samples from 1011 unique cancer cell lines to primarily define gene fusions [9].
Subsequently, whole-genome CRISPR-Cas9 drop-out screening was applied to identify gene fusions
required for cancer cell fitness [84–87,89]. Similar techniques may be applied to identify repositionable
anti-cancer drugs and propose new treatments by determining several fused genes as potential targets.
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Figure 4. Pipeline of drug repositioning for a specific cancer or other disease. First, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 dropout
screening is applied for a negative selection of survival essential genes. Second, the number of dropped out selected genes is diminished by collecting information
from databases and literature reviews. Third, in vivo CRISPR-Cas9 screening of an animal model of cancer or another disease will result in a few gene targets. Finally,
FDA-approved drugs or those which have passed primitive phases of clinical trials could be tested as inhibitors for discovering essential survival genes.
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5. Systems Biology Application in Drug Repositioning
Wet lab high-throughput approaches examine all possible targets to find a repurposable drug [90].
In this regard, computer-assisted systematic drug repurposing methods may overcome the limitations
associated with wet lab high-throughput techniques using focused resources based on knowledge of
the gene/protein target and literature [91].
Personalized drug repurposing may now be employed systematically [90] by employing a systems
medicine approach to handle the massive amounts of medical information which is accumulated in
DBs [92]. Five major categories may be employed to classify in silico drug repurposing methods,
namely network-based, machine learning, chemoinformatic-, bioinformatic-, and signature-based
approaches [90].
5.1. Network-Based Methods in Drug Repositioning
Network-based methods integrate various high-throughput data to address issues in drug
repositioning and drug combination. Specifically, they rely on known biological relationships of
drug–gene–metabolite–protein–disease to generate networks, of which DisGeNET [93], the Therapeutic
Target Database (TTD) [94], BindingDB [95], STRING [96], STITCH [97], and TCSBN [47] employ
network-based approaches. Key studies in the field have highlighted how network-based methods
may be employed for drug repositioning and drug combination. For instance, by quantifying
the network proximity of disease genes and drug targets [98] and also drug targets and disease
proteins [99] in the human (protein–protein) interactome, many novel drug–disease relationships for
over 900 FDA-approved drugs and clinically efficacious drug combinations for specific diseases were
identified. It should be noted that network-based methods are not alternatives, but complementary,
to experimental approaches, capable of systematically capturing and characterizing coordinated
cellular responses that would otherwise be technically challenging experimentally, further focusing
clinical-phase attention on precise objectives [100]. To accomplish these tasks, network-based methods
make use of various data, including phenotypic, drug-related, and molecular data, to construct
various network types, such as Drug–Drug Interaction Networks, Drug–Target Interaction Networks,
Drug–Disease Interaction Networks, and Multilayer Networks. By providing different biological
characterizations, network-based methods are thus excellent frameworks in drug repositioning [100].
The idea behind network-based cluster approaches which can reveal the drug–disease or drug–target
associations is that biological entities (e.g., diseases, drugs, and proteins) in the same module (also
known as subnetworks or groups) share similar features in a biological network. Network-based
approaches apply concepts from graph theory, where genes, drugs, diseases, or metabolites share
biologically-demonstrated or putative associations. A module can consist of drug–disease, drug–drug,
or drug–target relationships and this information can be extracted using the topological structure of a
network. Density-based spatial clustering of applications with noise (DBSCAN) [101], Ordering Points
To Identify the Clustering Structure (OPTICS), and the Statistical Information Grid (STING) [102]
are some examples of the algorithms employed in network analyses. Importantly, in many cases,
pleiotropic biological functions may occur; for instance, the proteins that are related to different cellular
functions and consequently contribute to pleiotropic phenotypes when mutated [103]. Employing a
k-means-based network cluster algorithm, chemical–protein interactions were recently used to uncover
repositionable drugs in small-cell lung cancer [104].
Network-based propagation methods may be divided into local (i.e., consider information from
a subset of the network’s nodes) [105] and global (i.e., derive information from the entire network)
methods [106]. These approaches apply prerequisite information from the source node(s) to other
network nodes [90,107]. The efficiency of these methods were proven for discovering disease–target,
disease–gene, and disease–drug connections [108], and have been shown to provide a higher efficacy
compared to other methods [106]. In addition, a comprehensive procedure based on formulating
constraints on a score function related to the smoothness of the disease–gene network may lead to the
discovery of disease–gene and disease–protein relationships [109]. This method could successfully
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predict gene targets for type 2 diabetes, Alzheimer’s disease, and prostate cancer [90]. Additionally,
methotrexate, gabapentin, cisplatin, donepezil, and risperidone could be repurposed for a second
indication through a disease–gene–drug network propagation approach [110]. These observations
indicate that drug repurposing conducted through network-based approaches presents an efficient
and systematic approach for proposing repurposable drugs.
Computational methods may also derive information from genome-scale metabolic networks
through the utilization of genome-scale metabolic models (GEMs). These are models that depict
gene–protein–reaction relationships for entire metabolic genes in an organism, and can be simulated
to predict metabolic fluxes for various systems-level metabolic studies [111]. For instance, a prostate
cancer (PRAD)-specific GEM was reconstructed to investigate prostate cancer metabolism by the
integration of global gene expression profiling of cell lines treated with more than 1000 different
drugs [112]. As a result, among sulfamethoxypyridazine, azlocillin, hydroflumethiazide, and ifenprodil,
as repositionable drugs proposed through an in silico cell viability assay, ifenprodil could be validated
using an in vitro cell assay. In another study [113], GEMs used for drug design were assessed.
In this regard, a list of human metabolites with KEGG [114] identifiers and their structures were
retrieved using an updated human GEM [115]. Drug structures were compiled from DRUGB [20]
and drug-metabolite pairs were analyzed. Finally, the effects of lipoamide analogs on MCF7 (a breast
cancer cell line) and airway smooth muscle (ASM) cells were proposed and subsequently successfully
demonstrated experimentally.
5.2. The Application of Machine Learning in Drug Repositioning
Machine-learning techniques have recently been employed to propose new drug
candidates [116,117], where supervised approaches predict potential associations between approved
drugs and health disorders [118]. For instance, the application of classification algorithms,
including logistic regression, random forest, and support vector machine algorithms, has been
conducted to construct prediction models and predict previously unknown pharmacological effects of
different compounds [119]. In this case, in order to define the associations between drugs and diseases,
four classes of drug-drug similarity (chemical structure, side-effects, gene ontology, and targets) and
three categories of disease-disease similarity (phenotypes, human phenotype ontology, and gene
ontology) were used. Finally, random forest methods exhibited the highest performance and could
predict novel indications for 20 existing drugs and 31 compounds, which were subsequently validated
using clinical trial data [119].
A swift escalation in the volume of biomedical literature has made it impossible to manually
discover all meaningful connections between biomedical concepts, especially drug repositioning,
which requires the integration of various aspects of biomedical knowledge. Hence, the automated
text mining of literature applies natural language processing to transform unstructured text from
various sources (databases, websites, books, reviews, and articles) into normalized, structured,
and quantifiable data and their connections [120]. Co-occurrence methods reveal the association
between two non-co-occurrence terms through discovering a third linking term that appears directly
with each of them [121]. Recently, a comprehensive study was conducted to evaluate different
drug repurposing strategies for Parkinson’s disease by text mining the scientific literature through
comparing various methods, including the extraction of biomedical entities and their relationships,
construction of a knowledge graph for Parkinson’s disease, knowledge representation learning,
and machine learning-based prediction [122]. As a result, unstructured biomedical literature data
were effectively transformed to structured data that could be directly used by modern computational
methods, such as machine learning [122]. Text-mining methods were recently applied, together with
network analyses, to create disease-specific drug–protein connectivity maps [123]. These approaches
extract disease–protein relationships from molecular interaction networks through network mining
and investigate PubMed abstracts to predict novel identify drug–protein associations. In this regards,
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diltiazem and quinidine, as hypertension and arrhythmia drugs, respectively, can be repurposed for
Alzheimer’s disease, which has been confirmed by clinical evidence.
The application of deep learning as a promising approach for capturing complex and highly
non-linear and heterogenous network structures has been actively explored. For instance [124],
10 drug–disease, one drug–side-effect, one drug–target, and seven drug–drug networks were integrated
by a network-based deep-learning approach for in silico drug repurposing. Eventually, in addition to
detecting an approved drug–disease association from the ClinicalTrials.gov database, repositionable
drugs and novel drug targets were proposed for Alzheimer’s disease (e.g., risperidone and aripiprazole)
and Parkinson’s disease (e.g., methylphenidate and pergolide).
5.3. Chemoinformatic-Based Methods in Drug Repositioning
Chemoinformatic approaches are one of the primary methods employed for screening
repositionable drugs and create chemical libraries submitted to an in silico screen. These approaches
are the basic components of many datasets, including DRUGB [20]. Using a similarity-based approach
that correlates the anatomical therapeutic chemical classes of drug indications and their similarity,
related therapeutic indications are proposed based on chemically similar drugs [125].
Ligand-based and structure-based approaches can be embedded in chemoinformatic-based drug
repurposing. The story behind these two methods is that analogous compounds are likely to have
similar biological properties [126] and proteins with almost the same structures tend to have similar
functions and bind identical compounds [127]. However, the drugs identified through these two
methods may share the same pathway with the template drug and accordingly, for a specific disease,
if the template drug has already been used as a treatment, the role of these techniques becomes
limited [128]. In addition, the lack of specificity is a serious drawback in this strategy. For instance,
thalidomide has two chiral forms (the same chemical composition, but having mirrored structures).
One can treat morning sickness, while the other form can have teratogen effects [129]. In this regard,
molecular docking has been introduced as the most commonly used tool for structure-based virtual
screening, in order to repurpose available drugs [130,131]. In this regard, Pinzi et al. repurposed
cannabigerol, which is a non-psychoactive cannabinoid, as a low micromolar inhibitor of the enoyl
acyl carrier protein reductase enzyme using an integrated ligand-based and structure-based study.
5.4. Bioinformatics-Based Methods in Drug Repositioning
From sequence alignment to domain similarity identification tools, a disease-centric approach is
known as one of the principles of bioinformatical drug repositioning that tends to find diseases with
the same dysfunctional proteins, which is often not clearly identified in experimental assays [90].
Local and global structural similarities are two different concepts; one can only be considered for
similar binding sites of non-evolutionary proteins with variable folding and functions, and the other one
is related to the whole structure of evolutionary proteins with considerable homology, respectively [132].
Ehrt et al. [127] claimed that the algorithms developed so far for binding site similarity assessments
are not convincing since adequate benchmarking studies have not been developed. Accordingly,
they suggested using a combination of in silico and experimental methods in a workflow to enhance
the accuracy.
5.5. Signature-Based Drug Repositioning
The idea behind signature-based drug repositioning is that if the gene expression signature of
a particular drug is opposite to the gene expression signature of a disease, that drug may have a
potential therapeutic effect on the disease [133]. Drug signatures can be retrieved by comparing
the gene expression profile of a cell line before and after its exposure to a specific drug. However,
it should be considered that gene signatures are often used to address the off-targets of drugs in network
pharmacology and these methods may not explain the relation between gene-expression alterations [134].
Some studies have tried to overcome this drawback through network-based analysis [133]. However,
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in complex disorders such as cancer [135], Alzheimer’s disease [136], and inflammatory bowel disease,
promising results were achieved through signature-based methods [137]. The Connectivity Map
(cMap) [138] project was later joined with the LINCS L1000 project [30], which are two comprehensive
and pioneer databases in the field of signature-based drug repurposing providing the gene expression
profiles of dozens of cell lines treated with thousands of small molecules. It is obvious that dealing with
such a large dataset would be challenging for computational systems biologists who aim to analyze
and visualize Big Data. The cMap project presents a valuable resource for conducting large-scale
assays of many small molecules. However, it is not without limitations. First, while comprehensive,
it has tested few cell lines. Second, it presents limited drug perturbation data and does not provide a
comprehensive view of drug dosages and temporal dynamics upon drug exposure. Third, because of
this, its application in other cell lines and biological samples is very limited and has been demonstrated
to not be very robust [139]. However, extensively examining a high number of small molecules,
with different dosages and time points, is an extremely expensive and time-consuming process.
Seeking to overcome these issues, others sought to devise systematic approaches to test a large
number of samples and compounds, while aiming to also provide a systematic view of intracellular
behavior (L1000). However, doing so is not without its perils, as previously mentioned with regards to
the computationally heavy process [139]. Accordingly, a systematic compound signature discovery
pipeline, called Enrichment of Gene Effect to a Molecule (EGEM), was developed by Liu et al. [140],
which was derived from a rank-based gene set enrichment analysis and showed a better performance
in comparison to the original. To date, several drug candidates have been proposed thanks to
signature-based studies of cMap and L1000 data, including KM-00927 and BRD-K75081836 as novel
histone deacetylase inhibitors and mitomycin C as a topoisomerase IIB inhibitor [141].
6. Conclusions and Future Direction
The integration of large assays is crucial for accurate predictions of potential therapeutic targets
from high-throughput assays. DBs store both computationally- and laboratory-based created data
and, subsequently, systems medicine makes use of these resources to decipher potential disease
mechanisms, targetable genes and pathways, and prognostic or theranostic features of biomarkers
(Figure 5). Omic data have been coupled with essentiality screens, including RNAi screening or the
more accurate CRISPR-Cas9 screens.
Several criteria are critical to facilitating DB usage in pharmaceutical science. First, one of the
most important features of a database is that it has to be publicly available. Second, the availability of
data after publication is another important criterion. Third, being updated in both data and interface
aspects is crucial for drug discovery. Fourth, having an application programming interface (API)
can help expert users to conveniently retrieve their required information, and many currently devise
APIs to enable computational scientists to easily retrieve and analyze their data (e.g., LINCS L1000
and CheMBL). Fifth, data and metadata should be uniformly deposited and easily retrievable. Sixth,
fully downloadable data are necessary for several experts to develop their own methods. LINCS L1000,
ENCODE, TTD, and DSDB are instances of databases with data that are available to download. Seventh,
internal tools such as the drug repositioning package of LINCS L1000 and SCYP can facilitate the use
of databases. Eighth, advanced searches and queries increase the capabilities of databases, for instance,
DrugDB and LINCS L1000 (Slicer, LINCS Canvas Browser, and L1000 Viewer). Researchers can make
use of the feature list and characterization provided here (Table 1 and Tabel S1, and Figure 2) as a
starting point to identify suitable datasets and other information for their research purposes.










































Figure 5. From bottom to the top, this is the whole story of current efforts to find repositionable drug
candidates for emerging disease. DBs, as the foundation of drug repositioning, can be created from
various computational and experimental approaches. The second way of categorizing DBs (assay-based
classification) is depicted here as three in silico and three laboratory-based approaches in yellow
gears to construct a DB. Afterwards, DBs can pave the way for various categorizations of systems
medicine (shown in green gears) to decipher many probabilities in the case of disease mechanisms;
disease stratification; therapy options; and diagnostic, prognostic, or theranostic features of biomarkers.
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Previously FDA-approved chemicals as drugs may be repurposed for new targets and their mode
of action and side effects can be investigated. Systematic drug repurposing requires a comprehensive
collection of all these small-molecule drugs. There are many comprehensive databases encompassing
various data types, and integrated perspectives such as those given by the DrugBank may facilitate
drug repositioning. Systems biology and systems medicine may assist in this effort by applying
machine learning and integrative approaches to predict repurposable drugs based on data from
different sources. In this case, method and algorithm development seems necessary to escalate the
efficiency of in silico screenings.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/9/2694/s1:
Table S1: An overview of all DBs discussed in this review in terms of the type of assay(s), data, and availability
of content.
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